CBD To Fight Schizophrenia; Round Two

 

GW Pharmaceuticals begins new study; a phase two clinical trial 

People living with schizophrenia, whose current medication is not fully effective, will participate in a new study to see if CBD is safe and effective when used alongside an anti-psychotic drug, according to a newly registered clinical trial. 

The research builds on the findings of a phase one study that showed lower levels of psychotic symptoms in participants who took the drug combo.

“CBD had beneficial effects in patients with schizophrenia.”

The first study, published in the American Journal of Psychiatry, suggested that: “CBD had beneficial effects in patients with schizophrenia.”

It said that CBD “may represent a new class of treatment for the disorder.”

The phase two study is expected to include approximately 366 patients in the randomized, double blind trial.

The clinical trial is in the “recruiting patients” phase and expected to have completed results in June 2022.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s